2013-03-19 15:38:55 -
ORION CORPORATION STOCK EXCHANGE RELEASE 19 MARCH 2013 4.35 P.M.
In its organising meeting, the Board of Directors of Orion Corporation, which
was elected today by the Annual General Meeting of the Shareholders, has
elected Jukka Ylppö as Vice Chairman. The compositions of the Board committees
were decided to be as follows:
Hannu Syrjänen, Chairman
Heikki Westerlund, Chairman
Sirpa Jalkanen, Chairman
The members to the Nomination Committee will be elected later.
The Board of Directors has assessed the independence of its members and
concluded that all the
members are independent of the company and its
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE